Therapeutic | Ustekinumab |
Target | IL12B |
Heavy Chain | EVQLVQSGAEVKKPGESLKISCKGSGYSFTTYWLGWVRQMPGKGLDWIGIMSPVDSDIRYSPSFQGQVTMSVDKSITTAYLQWNSLKASDTAMYYCARRRPGQGYFDFWGQGTLVTVSS |
Light Chain | DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNIYPYTFGQGTKLEIK |
100% seqID Fv Structure | 3hmw [Fvs: HL], 3hmx [Fvs: HL] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
100% seqID Structure | 3hmw [Fvs: HL] |
100% seqID Structure | 3hmx [Fvs: HL] |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (August '23) | Approved |
Estimated Status (August '23) | Active |
Recorded Developmental Technology | Medarex UltiMAb Mouse |
INN Year Proposed | 2008 |
INN Year Recommended | 2009 |
Companies Involved | Centocor Inc, Janssen Biotech, Medarex |
Conditions Approved | Crohn's disease, Plaque psoriasis, Psoriatic arthritis |
Conditions Active | Ulcerative colitis, Spondylarthritis, Systemic lupus erythematosus, Atopic dermatitis |
Conditions Discontinued | Multiple sclerosis, Palmoplantar pustulosis, Primary biliary cirrhosis, Rheumatoid arthritis, Sarcoidosis |
Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]